Wood H, Chandler A, Nezamololama N, et al. - In patients with Atopic dermatitis (AD), all studies reported that Janus kinase (JAK) inhibitors were well tolerated in comparison with the control group. Trials reported to date are of short duration (maximum 16 weeks), and there is a need for more information on the long-term safety of these novel agents, while the use of JAK inhibitors in patients suffering from AD is very promising,

• Researchers demonstrated the safety results of clinical trials using oral abrocitinib, upadacitinib, and baricitinib, as well as topical ruxolitinib and delgocitinib for the treatment of AD.

• Nausea, upper respiratory tract infection, headache, herpes zoster, herpes simplex, acne, increased blood creatine phosphokinase levels, and decreased platelet counts were the most prevalent (2–5% occurrence rate) treatment-emergent adverse events from oral JAK inhibitor use in AD.

• It was shown that topical JAK inhibitors were not associated with systemic effects.